Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Praxis Precision Medicines ( (PRAX) ) just unveiled an announcement.
On October 21, 2025, Praxis Precision Medicines updated its corporate presentation for investors and analysts, highlighting its recent progress and future plans. The company announced that the FDA granted a Type B meeting for its drug candidate ulixacaltamide, following the review of the Essential3 topline results, indicating a significant step forward in its regulatory process for treating essential tremor.
The most recent analyst rating on (PRAX) stock is a Hold with a $181.00 price target. To see the full list of analyst forecasts on Praxis Precision Medicines stock, see the PRAX Stock Forecast page.
Spark’s Take on PRAX Stock
According to Spark, TipRanks’ AI Analyst, PRAX is a Neutral.
Praxis Precision Medicines’ stock score is primarily impacted by its poor financial performance, characterized by significant net losses and negative cash flows. However, the strong technical indicators and positive earnings call sentiment, highlighting promising clinical trial results and a robust pipeline, provide some optimism. The valuation remains a concern due to the negative P/E ratio and lack of dividend yield.
To see Spark’s full report on PRAX stock, click here.
More about Praxis Precision Medicines
Praxis Precision Medicines operates in the biotechnology industry, focusing on developing precision medicines for central nervous system (CNS) disorders. The company utilizes platforms such as the Cerebrum small molecule platform and the Solidus antisense oligonucleotide platform to create therapies targeting specific neurological conditions.
Average Trading Volume: 755,745
Technical Sentiment Signal: Buy
Current Market Cap: $3.71B
For an in-depth examination of PRAX stock, go to TipRanks’ Overview page.